SHANGHAI – Shanghai-based Generon Corp. Ltd. was acquired by the world's leading manufacturer of vitamin B5 API, Yifan Pharmaceutical Co. Ltd., a public company listed in Shenzhen. Yifan has a portfolio of drugs approved in China for gynecology, pediatrics and dermatology, a portion of which are traditional Chinese medicine (TCM) products.
SHANGHAI – Acea Biosciences Inc. presented efficacy, safety and tolerability data from its China phase I/II dose-escalation and expansion study of AC0010, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) at the World Conference on Lung Cancer (WCLC) 2016 in Vienna.
SHANGHAI – Shanghai-based Generon Corp. Ltd. was acquired by the world's leading manufacturer of vitamin B5 API, Yifan Pharmaceutical Co. Ltd., a public company listed in Shenzhen. Yifan has a portfolio of drugs approved in China for gynecology, pediatrics and dermatology, a portion of which are traditional Chinese medicine (TCM) products.
SHANGHAI – Acea Biosciences Inc. presented efficacy, safety and tolerability data from its China phase I/II dose-escalation and expansion study of AC0010, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) at the World Conference on Lung Cancer (WCLC) 2016 in Vienna.
SHANGHAI – Shanghai-based Hutchison Medipharma Co. Ltd. presented phase I data for epitinib at the World Conference on Lung Cancer in Vienna showing that epitinib is a safe EGFR inhibitor with the ability to cross the blood-brain barrier (BBB).
SHANGHAI – Bioatla LLC, of San Diego, has received $36 million from Chinese conglomerate Beijing Sinobioway Group Co. Ltd. in a co-development partnership that has netted the American partner $100 million in program payments and equity investments.
SHANGHAI – Shanghai-based Hutchison Medipharma Co. Ltd. presented phase I data for epitinib at the World Conference on Lung Cancer in Vienna showing that epitinib is a safe EGFR inhibitor with the ability to cross the blood-brain barrier (BBB).
SHANGHAI – More than five years in the making, the FDA has granted Suzhou Alphamab Co. Ltd. clinical trial approval in the U.S. for KN035, an anti-PD-L1 single-domain agent discovered, developed and manufactured in China.
SHANGHAI – More than five years in the making, the FDA has granted Suzhou Alphamab Co. Ltd. clinical trial approval in the U.S. for KN035, an anti-PD-L1 single-domain agent discovered, developed and manufactured in China.
SHANGHAI – Innovent Biologics Inc., of Suzhou, has raised $260 million from government-backed and independent investors in what is the largest financing round ever for a private biopharma in China. The deal is also the second largest for the sector globally this year.
